Market Intelligence, Clinical Progress, and High-Purity Reagents for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Hyponatremia, and Nephrogenic Diabetes Insipidus (NDI) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AVPR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Receptor Expression | AVPR2 Lentivirus Premade Particles High titer (>10^8 TU/mL), Sequence Verified, HEK293T packaged. Optimized for stable cell line construction preserving native 7-TM GPCR conformation. |
View AVPR2 Products |
| Gene Delivery | AVPR2 Promise-ORF Full-length ORF with native signaling domains. Codon optimized for mammalian expression systems. |
View AVPR2 Products |
| Benchmark Ab | Anti-AVPR2 Control Antibody Recombinant positive control for flow cytometry and target validation. |
View AVPR2 Products |
| Validator | AVPR2 siRNA Set For knockdown verification and pathway isolation in calcium flux and cAMP functional assays. |
View AVPR2 Products |
| Related Target A | AVPR1A (V1aR) Critical for subtype selectivity and vascular off-target counter-screening. 41% homology with AVPR2. |
View AVPR1A Products |
| Related Target B | AQP2 (Aquaporin-2) Downstream effector of AVPR2 activation in renal collecting ducts; synergistic readout for NDI and PKD programs. |
View AQP2 Products |
| Related Target C | OXTR (Oxytocin Receptor) Structural homology requires counter-screening to avoid reproductive system off-target effects. |
View OXTR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex GPCR Conformation & Membrane Topology | High-titer Lentivirus for stable HEK293/CHO cell line generation, ensuring multipass membrane insertion and native glycosylation. |
| Subfamily Counter Screening | Homolog panel (AVPR1A, AVPR1B) lentiviral tools available for strict selectivity profiling. Human / Cyno / Mouse ortholog reagents available. |
| Pharmacochaperone Rescue of NDI Mutants | Premade mutant lentivirus particles (R137H, W164S, L312X) with sequence-verified ORFs for cAMP rescue and cell-surface restoration assays. |
| Lack of Positive Controls | Sequence-verified Benchmark Antibodies included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for precise specificity checks in binding and functional assays. |
Live AVPR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AVPR2 (V2R) therapeutics is evolving, with major players shifting focus from first-generation hepatotoxic small molecule antagonists to highly selective next-generation modulators, biologics, and gene therapy approaches. As pioneer therapies like Tolvaptan and Desmopressin cement the target's clinical validity in ADPKD and diabetes insipidus, the next wave of R&D is heavily targeting enhanced safety profiles, strict V2-over-V1 selectivity, and combinations with metabolic modulators. Significant unmet need persists in X-linked nephrogenic diabetes insipidus (XNDI), where mutant receptor rescue via pharmacochaperones represents a mechanistically differentiated frontier. Precision targeting using nanobodies, advanced peptide mimetics, and allosteric modulators is becoming a central strategy to mitigate off-target liabilities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Otsuka (Tolvaptan), Sanofi, BioCryst (Lixivaptan) | ADPKD, Hyponatremia, Heart Failure | Selectivity Assay (Need AVPR1A/AVPR1B lentivirus for counter-screens) |
| Peptide Agonist | Ferring Pharmaceuticals, Bio-Thera | Diabetes Insipidus, Bleeding Disorders | Receptor Activation (Need robust GPCR stable cell lines for cAMP accumulation & internalization assays) |
| Pharmacochaperone | Academic / Biotech (Emerging) | XNDI (Mutant Rescue) | Cell Surface Rescue Assay (Need full-length mutant AVPR2 lentivirus stable lines) |
| Biologics / Nanobodies | Emerging Biotechs | Refractory ADPKD | Conformation Preservation (Need HEK293-expressed native receptor tools) |
| Gene Therapy | Various Academic Labs | Congenital NDI (AVPR2 mutations) | Mutant Validation (Need disease variant ORFs in lentiviral backbone) |
| Allosteric Modulators | Preclinical | Cardiovascular | Calcium Flux Assay (Full-length GPCR required in stable cell line) |
Key Mutations & Genetic Variants
Key mutations in AVPR2 include those associated with NDI and drug response: in dbSNP:rs5196 (UniProt P30518 VAR_003516), in dbSNP:rs2071126 (UniProt P30518 VAR_015296), and in dbSNP:rs5198 (UniProt P30518 VAR_011858). These variants are critical for understanding receptor function and developing targeted therapies.